Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

Home
/
update
/
details

Lucid Diagnostics Secures Key Patent Allowance for EsoGuard Esophageal DNA Test

NextEdge Admin

16 Oct 2024

2 min 28 sec

next-generation sequencing,esophageal cancer

Lucid Diagnostics , a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent application. The patent covers Lucid’s proprietary method using methylation of the cyclin-A1 (CCNA1) gene to detect esophageal precancer and cancer, a core feature of the EsoGuard® Esophageal DNA Test.

“This patent enhances our already strong intellectual property portfolio and provides robust protection for the CCNA1 methylation assay, a critical component of the EsoGuard test,” said Lishan Aklog, M.D., Lucid’s Chairman and CEO. “It validates our strategic focus on the laboratory methods of the assay, a path we will continue to pursue for other components.”

The EsoGuard test applies next-generation sequencing (NGS) technology to assess DNA methylation at 31 sites on two genes—vimentin (VIM) and cyclin-A1 (CCNA1). While VIM methylation had been linked to gastrointestinal neoplasias, the association between CCNA1 methylation and esophageal neoplasia is novel and demonstrates higher specificity for conditions like Barrett’s Esophagus (BE) and esophageal adenocarcinoma.

The technology behind EsoGuard and the EsoCheck® Esophageal Cell Collection Device was developed by faculty from Case Western Reserve University (CWRU) with support from the National Institutes of Health (NIH). Lucid holds exclusive global licensing rights to commercialize the technology, which was transferred from research to market through close collaboration with CWRU.

Lucid focuses on patients with chronic GERD, aiming to prevent esophageal cancer through early detection using noninvasive tools like EsoGuard and EsoCheck.